Clinical Trial Closeup
A potential gene therapy to treat Stargardt
Phase II results identify patients with macular degeneration phenotype may benefit most from the investigative transgene therapy.
Transgene shows restorative properties in nAMD
4D-150 is an intravitreal dual transgene genetic medicine that expresses both aflibercept and an mRNAi sequence that inhibits intracellular expression of VEGF-C.
Potential of low-light therapy for dry AMD
Trial shows effectiveness of the Valeda Light Delivery System photobiomodulation platform.
Reviving dormant photoreceptors in LCA1
The gene therapy ATSN-101 has demonstrated safety and shown signals of efficacy in restoring vision in Leber congenital amaurosis.
A pill to head off worsening of DRSS
A Phase III trial is on deck for the oral Ref-1 inhibitor APX3330 after a Phase IIb study showed a potential benefit.
Axitinib implant shows early potential
Interim results from Phase I trial of OTX-TKI, a bioresorbable hydrogel platform using a tyrosine kinase inhibitor.
Senolytic therapy: ‘Entirely new paradigm’
A look at UBX1325, a small-molecule B-cell inhibitor that targets the proteins senescent cells feed on for survival.
Sustained-release sunitinib comes to retina
A closer look at the extension study of GB-102 for treatment of neovascular age-related macular degeneration.
A potential stem-cell solution for GA
Trial shows safety of a biosynthetic patch inserted in a subretinal bleb in an outpatient procedure.
Targeting headwaters of classical pathway
The IgG antibody fragment ANX007 aims to disrupt the cascade that leads to geographic atrophy at the initiating molecule.
Current Issue
Continuing Medical Education
Additional Publications
Tuesday, October 8, 2024 | Learn More About Stargardt Disease
Location: Webinar
Time: 7:00 PM ET
Time: 7:00 PM ET
Speaker: Lejla Vajzovic, MD, FASRS
Sponsored by Alkeus Pharmaceuticals, Inc.
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
